Oramed Pharmaceuticals Inc.
NASDAQ:ORMP · NASDAQ Capital Market
+$0.03 today
Vol 0.15M · Avg 0.16M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $64.0M +435.9% | -$19.1M -445.0% | $5.5M +115.1% | -$36.6M -64.4% | -$22.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $121.0K -37.3% | $193.0K -1.5% | $196.0K +237.9% | $58.0K -24.7% | $77.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $7.9M | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $6.0M | $0 | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.9M -159.6% | $3.2M +218.7% | -$2.7M -185.9% | -$943.0K +28.3% | -$1.3M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $1.1M -67.9% | $3.5M +258.4% | -$2.2M -491.8% | -$376.0K -118.3% | $2.1M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$3.0M -834.5% | -$325.0K +31.0% | -$471.0K +16.9% | -$567.0K +83.2% | -$3.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$85.3M -1275.4% | $7.3M +154.5% | -$13.3M -252.3% | $8.7M +281.0% | $2.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$9.1M -8.7% | -$8.4M +18.3% | -$10.3M +64.1% | -$28.7M -35.5% | -$21.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.9M -10639.5% | -$18.0K +92.9% | -$254.0K +48.8% | -$496.0K -32.3% | -$375.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$7.3M | $0 | $0 -100.0% | $24.0K -98.4% | $1.5M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$88.5M -58.7% | -$55.8M +70.8% | -$190.9M -23.6% | -$154.4M -186.9% | -$53.8M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $96.9M -40.1% | $161.7M +36.8% | $118.1M -36.2% | $185.1M +508.2% | $30.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $6.3M +10518.3% | -$60.0K | $0 -100.0% | $2.0K +299.9% | -$1.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $5.4M -94.9% | $105.8M +244.9% | -$73.0M -341.8% | $30.2M +235.7% | -$22.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$49.5M -200.0% | $49.5M | — | — | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 -100.0% | $2.4M -79.0% | $11.6M -88.6% | $101.4M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$4.7M -90.9% | -$2.5M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 +100.0% | -$2.0K | $0 | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$4.7M +90.9% | -$52.0M -200.1% | $52.0M +349.6% | $11.6M -88.6% | $101.4M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$30.0K -650.0% | -$4.0K +92.6% | -$54.0K +99.9% | -$49.9M -2492750.0% | $2.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$8.5M -118.7% | $45.4M +244.4% | -$31.4M +14.6% | -$36.8M -163.5% | $57.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$11.1M -31.4% | -$8.4M +20.1% | -$10.5M +63.9% | -$29.2M -35.4% | -$21.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
MacroGenics, Inc.
NASDAQ:MGNX
$258.41M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.81M
InflaRx N.V.
NASDAQ:IFRX
$130.74M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.30M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$90.90M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.27M
ImageneBio Inc
NASDAQ:IMA
$63.61M
Clene Inc.
NASDAQ:CLNN
$60.71M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.16M
SEC Filings
Recent regulatory filings
No filings found.
Does ORMP generate free cash flow?
Oramed Pharmaceuticals Inc. (ORMP) generated -$11,078,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does ORMP produce?
Operating cash flow was -$9,145,000.00, before capital expenditures of $1.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.